Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 2, 2012, Pages

  Jain, Ajay Kumar ^a   Stoll, Barbara ^a   Burrin, Douglas G ^a   Holst, Jens J ^b   Moore, David D ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chenodeoxycholic acid; Fibroblast growth factor 15 19; Glucagon like peptide 1; Glucagon like peptide 2; Total parenteral nutrition

Indexed keywords

BILE ACID; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 19; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; ENTERIC FEEDING; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISTOLOGY; INSULIN BLOOD LEVEL; INTESTINE MUCOSA; INTESTINE MUCOSAL ATROPHY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER FUNCTION; NONHUMAN; PRIORITY JOURNAL; SWINE; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

ANIMALS; ANIMALS, NEWBORN; ATROPHY; CHENODEOXYCHOLIC ACID; CHOLESTASIS; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; GLUCAGON-LIKE PEPTIDES; INTESTINAL MUCOSA; LIVER DISEASES; PARENTERAL NUTRITION, TOTAL; SWINE; TREATMENT OUTCOME;

EID: 84855334407     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00280.2011     Document Type: Article

References (30)

1. Al-Mukhtar MY, Sagor GR, Ghatei MA, Bloom SR, Wright NA. The role of pancreatico-biliary secretions in intestinal adaptation after resection, and its relationship to plasma enteroglucagon. Br J Surg 70: 398-400, 1983.
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
3. Burrin DG, Stoll B, Guan X, Cui L, Chang X, Holst JJ. Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 146: 22-32, 2005.
4. Burrin DG, Stoll B, Jiang R, Chang X, Hartmann B, Holst JJ, Greeley GH Jr, Reeds PJ. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough? Am J Clin Nutr 71: 1603-1610, 2000.
5. Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol 4: 277-287, 2007.
6. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966, 2009.
7. DeRubertis FR, Craven PA, Saito R. Bile salt stimulation of colonic epithelial proliferation. Evidence for involvement of lipoxygenase products. J Clin Invest 74: 1614-1624, 1984.
8. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145: 2594-2603, 2004.
9. Howard L, Ament M, Fleming CR, Shike M, Steiger E. Current use and clinical outcome of home parenteral and enteral nutrition therapies in the United States. Gastroenterology 109: 355-365, 1995.
10. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 56: 2501-2510, 2007.
11. Hwang ST, Henning SJ. Ontogenic regulation of components of ileal bile acid absorption. Exp Biol Med (Maywood) 226: 674-680, 2001.
12. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2: 217-225, 2005.
13. Jones S. Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm 5: 42-48, 2008.
14. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 130: S70-77, 2006.
15. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 284: 1362-1365, 1999.
16. Niinikoski H, Stoll B, Guan X, Kansagra K, Lambert BD, Stephens J, Hartmann B, Holst JJ, Burrin DG. Onset of small intestinal atrophy is associated with reduced intestinal blood flow in TPN-fed neonatal piglets. J Nutr 134: 1467-1474, 2004.
17. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
18. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, Burgess SC, Mangelsdorf DJ, Kliewer SA. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 13: 729-738, 2011.
19. Rager R, Finegold MJ. Cholestasis in immature newborn infants: is parenteral alimentation responsible? J Pediatr 86: 264-269, 1975.
20. Roy CC, Laurendeau G, Doyon G, Chartrand L, Rivest MR. The effect of bile and of sodium taurocholate on the epithelial cell dynamics of the rat small intestine. Proc Soc Exp Biol Med 149: 1000-1004, 1975.
21. Sato H, Macchiarulo A, Thomas C, Gioiello A, Une M, Hofmann AF, Saladin R, Schoonjans K, Pellicciari R, Auwerx J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 51: 1831-1841, 2008.
22. Sigalet DL. Short bowel syndrome in infants and children: an overview. Semin Pediatr Surg 10: 49-55, 2001.
23. Stoll B, Horst DA, Cui L, Chang X, Ellis KJ, Hadsell DL, Suryawan A, Kurundkar A, Maheshwari A, Davis TA, Burrin DG. Chronic parenteral nutrition induces hepatic inflammation, steatosis, and insulin resistance in neonatal pigs. J Nutr 140: 2193-2200, 2010.
24. Teitelbaum DH. Parenteral nutrition-associated cholestasis. Curr Opin Pediatr 9: 270-275, 1997.
25. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177, 2009.
26. Toledo A, Yamaguchi J, Wang JY, Bass BL, Turner DJ, Strauch ED. Taurodeoxycholate stimulates intestinal cell proliferation and protects against apoptotic cell death through activation of NF-kappaB. Dig Dis Sci 49: 1664-1671, 2004.
27. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143: 1741-1747, 2002.
28. Wang H, Khaoustov VI, Krishnan B, Cai W, Stoll B, Burrin DG, Yoffe B. Total parenteral nutrition induces liver steatosis and apoptosis in neonatal piglets. J Nutr 136: 2547-2552, 2006.
29. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem 275: 15482-15489, 2000.
30. Zamir O, Nussbaum MS, Bhadra S, Subbiah MT, Rafferty JF, Fischer JE. Effect of enteral feeding on hepatic steatosis induced by total parenteral nutrition. JPEN J Parenter Enteral Nutr 18: 20-25, 1994.